Search for drugs:
Typing the drug name to query
LOMITAPIDE MESYLATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Effects on QT Interval
- At a concentration 23 times the Cmax of the maximum recommended dose, lomitapide does not prolong QTc to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
12482
38369105
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- C10AX12 - lomitapide mesylate
- C10AX - Other lipid modifying agents
- C10A - "LIPID MODIFYING AGENTS, PLAIN"
- C10 - LIPID MODIFYING AGENTS
- C - CARDIOVASCULAR SYSTEM
Active Ingredient:LOMITAPIDE MESYLATE
Active Ingredient UNII:X4S83CP54E
Drugbank ID:DB08827
PubChem Compound:9853053
CTD ID:C473731
PharmGKB:PA166114922
CAS Number:182431-12-5
Dosage Form(s):capsule
Route(s) Of Administrator:oral
Daily Dose:
- 40.0 mg/day C10AX12
Chemical Structure: 
SMILE Code:
FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12
FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.